SCHEMBL877094

SCHEMBL877094

CCCCOc1cccc(C)c1[N+](=O)[O-]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
TDP1 Q9NUW8 1/20 0.55
TSHR P16473 1/20 0.49
HPGD P15428 2/20 0.44
POLB P06746 1/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
RECQL P46063 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
TP53 P04637 1/20 0.43
KAT2B Q92831 1/20 0.43
TLR4 O00206 1/20 0.43
TLR2 O60603 1/20 0.43
KMT2A Q03164 4/20 0.42
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 2/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16143752 0.94 ALDH1A1 (0.51) ALDH1A1TDP1TSHRHPGDPOLB
SCHEMBL13476222 0.92 ALDH1A1 (0.56) ALDH1A1TDP1TSHRHPGDPOLB
Hydrochloric Acid SCHEMBL514641 0.89 ALDH1A1 (0.53) ALDH1A1TDP1TSHRHPGDPOLB
SCHEMBL8917747 0.88 ALDH1A1 (0.55) ALDH1A1TDP1TSHRHPGDPOLB
SCHEMBL27236467 0.86 ALDH1A1 (0.53) ALDH1A1TDP1TSHRHPGDPOLB
SCHEMBL9474904 0.85 ALDH1A1 (0.60) ALDH1A1TDP1TSHRHPGDPOLB
Hydrochloric Acid SCHEMBL514640 0.85 KAT2B (0.57) ALDH1A1TDP1TSHRHPGDPOLB
SCHEMBL13476249 0.84 ALDH1A1 (0.55) ALDH1A1TDP1TSHRHPGDPOLB
SCHEMBL837892 0.84 ALDH1A1 (0.55) ALDH1A1TDP1TSHRHPGDPOLB
SCHEMBL8973566 0.84 NPC1 (0.56) ALDH1A1TDP1TSHRPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117645562-A Ligand for copper catalytic coupling reaction and application thereof 江西德璟生物科技有限公司 2024-03-05 CN disclosed
EP-3081214-A2 INHIBITORS OF CELLULAR NECROSIS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2016-10-19 EP disclosed
EP-2384753-B1 Hydantoin derivatives as inhibitors of cellular necrosis BRIGHAM & WOMENS HOSPITAL (US) 2016-01-06 EP disclosed
US-8741942-B2 Inhibitors of cellular necrosis PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-06-03 US disclosed
US-20120149702-A1 INHIBITORS OF CELLULAR NECROSIS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-06-14 US disclosed
US-8143300-B2 Inhibitors of cellular necrosis PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-03-27 US disclosed
EP-2384753-A1 Hydantoin derivatives as inhibitors of cellular necrosis The Brigham and Women's Hospital, Inc. (US) 2011-11-09 EP disclosed
US-20110144169-A1 Inhibitors of cellular necrosis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-06-16 US disclosed
US-7592332-B2 Cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-09-22 US disclosed
US-7491743-B2 Inhibitors of cellular necrosis PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-02-17 US disclosed
US-20090023701-A1 Cytokine Inhibitors AUNGST RONALD A 2009-01-22 US disclosed
EP-1867646-A1 Cytokine inhibitors Boehringer Ingelheim Pharmaceuticals, Inc. (US) 2007-12-19 EP disclosed
US-20070275946-A1 Cytokine Inhibitors AUNGST RONALD A 2007-11-29 US disclosed
US-7285545-B2 N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023701-A1 Cytokine Inhibitors IL1B, TNF, IL1A ALDH1A1 297/4885TDP1 4566/4885TSHR 3979/4885
US-20110144169-A1 Inhibitors of cellular necrosis TNF, AIFM1, BAD ALDH1A1 2543/4885TDP1 392/4885TSHR 3079/4885
US-20070275946-A1 Cytokine Inhibitors IL1B, TNF, IL1A ALDH1A1 297/4885TDP1 4566/4885TSHR 3979/4885
US-20120149702-A1 INHIBITORS OF CELLULAR NECROSIS TNF, AIFM1, BAD ALDH1A1 2543/4885TDP1 392/4885TSHR 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.